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Introduction: The use of discharge β-blockers after cardiac surgery is associated with a
long-term mortality benefit. β-Blockers have been suggested to be less effective in black
cardiovascular patients compared with whites. To date, racial differences in the long-term
survival of coronary artery bypass grafting (CABG) patients who receive β-blockers at
discharge have not been examined.
Methods: A retrospective cohort study was conducted on patients undergoing CABG
between 2002 and 2011. Long-term survival was compared in patients who were and
who were not discharged with β-blockers. Hazard ratios (HR) and 95% confidence inter-
vals (CI) were computed using a Cox regression model. P-for-interaction between race and
discharge β-blocker use was computed using a likelihood ratio test.
Results:A total of 853 (88%) black (n=970) and 3,038 (88%) white (n=3,460) patients had
a history of β-blocker use at discharge (N =4,430). Black patients who received β-blockers
survived longer than those not receiving β-blockers and the survival advantage was compa-
rable with white patients (black, adjusted HR=0.33, 95% CI=0.23–0.46; white, adjusted
HR=0.48, 95% CI= 0.39–0.58; p-for-interaction=0.74). Among patients discharged on β-
blockers, we did not observe a long-term survival advantage for white compared with black
patients (HR=1.2, 95% CI=0.95–1.5).
Conclusion: β-Blocker use at discharge was associated with a survival advantage among
black patients after CABG and a similar association was observed in white patients.
Keywords: outcomes, CABG, epidemiology, β-blockers, cardiology
INTRODUCTION
Coronary heart disease (CHD) is the cause of 1 in 6 deaths in the
United States (1). Over the next 20 years, the prevalence of car-
diovascular disease, including CHD, will increase by 10% with a
threefold increase in cost (2). Modifiable risk factors (e.g., smok-
ing, diet, obesity) lead to an increased risk of CHD and reductions
in CHD mortality have been observed and attributed to public
health programs of smoking cessation and the implementation of
cholesterol and antihypertensive medications to patients at-risk
for the development of CHD (3).
An estimated 397,000 coronary artery bypass grafting (CABG)
procedures are performed annually in the United States with an
estimated direct and indirect cost approaching $181 billion (4).
Between 1980 and 2000, the age-adjusted death rate due to CHD
fell by 48% with 50% of this decrease being attributed to secondary
preventative measures in patients with known CHD, such as the
optimization of medical therapies after myocardial infarction (MI)
and revascularization procedures, including CABG (5). Due to the
projected increases in CHD prevalence and the known benefit of
CABG, the identification of therapies that improve outcomes in
the post-surgical population is of paramount importance.
Several studies have reported that black race is associated with
decreased long-term survival after CABG compared with whites
(6–10). In patients who have undergone CABG, those discharged
on β-blockers have been reported to survive longer compared with
those not discharged on β-blockers (11–13). However, racial dif-
ferences in β-blocker efficacy have been reported in heart failure
patients, suggesting that these therapies are less effective in black
compared with white patients (14). Potentially, similar differences
exist in the CABG population who are prescribed β-blockers at
the time of discharge. The purpose of this study was to exam-
ine the association of discharge β-blockers on long-term survival
among black CABG patients and to compare the magnitude of this
association with white patients.
MATERIALS AND METHODS
This analysis and a waiver of consent were approved by the Insti-
tutional Review Board at the Brody School of Medicine, East
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Carolina University. Details of the study database and method-
ology have been previously described and are briefly summarized
below (15–17).
STUDY DESIGN
This was a retrospective cohort study of patients undergoing first-
time, isolated CABG at the East Carolina Heart Institute between
July 2002 and May 2011. Demographic data, comorbid conditions,
coronary artery disease (CAD) severity, and surgical data were
collected at the time of surgery. Patients who were and were not
discharged on β-blockers were compared. Only black and white
patients were included to minimize the potential for residual con-
founding (~1% other races). Racial identity was self-reported.
Emergent cases were considered a different population due to
clinical instability and were excluded in our analysis (n= 98).
DEFINITIONS
A history of β-blocker use at discharge was the exposure variable
of interest. Mortality was defined as any cause of death postopera-
tively. CAD was defined as at least 50% stenosis and confirmed by
angiography before surgery.
SETTING
The East Carolina Heart Institute is a population-based tertiary
referral heart hospital located in the center of eastern North Car-
olina, a rural region with a large black population (18). The
institute is the largest stand-alone hospital devoted to cardio-
vascular care in the state of North Carolina, with an emphasis
on reducing the unequal burden of cardiovascular disease in this
region. The center provides care to patients that predominantly
live and remain within a 150-mile radius of the medical center.
DATA COLLECTION AND FOLLOW-UP
The primary sources of data were the Society of Thoracic Sur-
geons Adult Cardiac Surgery Database linked with the electronic
medical record at the Brody School of Medicine. The National
Death Index was used to obtain death dates for patients lost to
follow-up and also used to validate death information captured in
our electronic medical record. Linkage with the National Death
Index was based on a multiple criteria, deterministic matching
algorithm, which included a patient’s social security number (19).
In our database,<5% of validated deaths failed to correctly match
with the National Death Index. Beginning in 2012, the use of social
security numbers as a patient identifier was proscribed within our
university system in compliance with §205(r) of the Social Secu-
rity Act (20). Information on β-blocker use at discharge was not
collected in our database prior to 2002.
STATISTICAL ANALYSIS
Categorical variables were reported as frequency and percent-
age while continuous variables were reported as mean± standard
deviation, median, and range. Follow-up time was measured
from the date of surgery to the date of death or censoring.
Survival probabilities were computed using the Kaplan–Meier
product-limit method and stratified by β-blocker status. The
log-rank test was used to compare survival between patients
with and without discharge β-blockers. Cox proportional haz-
ard regression models were used to compute hazard ratios (HR)
and 95% confidence intervals (CI) for long-term mortality. The
main model was adjusted for variables that have been pre-
viously reported to be associated with cardiovascular-related
mortality and included the following covariates: age, sex, race,
hypertension, CAD severity, heart failure, and prior stroke. The
post hoc addition of other variables into the model was per-
formed in a pairwise fashion. P-for-interaction between race and
discharge β-blocker use was computed using a likelihood ratio
test. The test statistic of Grambsch and Therneau was used to
check the proportional hazards assumption (21). Temporality
during the study period was assessed by stratifying the analy-
sis by two time periods (e.g., 2002–2006, 2007–2011). There
were no missing values for the variables used in this analy-
sis. Statistical significance for categorical variables was tested
using Fisher’s exact test and the Deuchler–Wilcoxon procedure
for continuous variables. Statistical significance was defined as
p< 0.05. SAS Version 9.3 (Cary, NC, USA) was used for all
analyses.
RESULTS
A total of 853 (88%) black (n= 970) and 3,038 (88%) white
(n= 3,460) patients had a history of β-blocker use at discharge
(N = 4,430). Patient characteristics are described in Table 1. Pre-
operative medications and postoperative complications are shown
in Tables 2 and 3, respectively. The median follow-up for study
participants was 4.3 years.
Five-year survival for black patients with and without discharge
β-blockers was 86% and 59%, respectively (p< 0.0001) (Figure 1).
In whites, 5-year survival for patients discharged on β-blockers was
87% compared with 70% for patients without dischargeβ-blockers
(p< 0.0001) (Figure 2).
CABG patients receiving β-blockers at discharge sur-
vived significantly longer than those not receiving β-blockers
(blacks: unadjusted HR= 0.31, 95% CI= 0.22–0.43, adjusted
HR= 0.33, 95% CI= 0.23–0.46; whites: unadjusted HR= 0.40,
95% CI= 0.33–0.48; adjusted HR= 0.48, 95% CI= 0.39–0.58; p-
for-interaction= 0.74). Among patients discharged on β-blockers,
we did not observe a long-term survival advantage for white com-
pared with black patients (HR= 1.2, 95% CI= 0.95–1.5). The
main result was not substantively altered (±10% change in effect
size) with the pairwise addition of other variables listed in Table 1
or preoperative β-blockers.
DISCUSSION
A survival benefit was observed among black CABG patients
who received discharge β-blockers and the magnitude of this
association was comparable with white patients. Recent studies
have focused on the impact of preoperative β-blockers and their
influence on short-term mortality (22, 23). Only a few studies
have looked at the impact of these medications at discharge on
long-term survival after CABG (11–13).
An investigation of 3,102 patients discharged on β-blockers
after cardiac surgery reported that patients using these medica-
tions were more likely to be alive 6 years after surgery compared
with those not discharged on β-blockers (adjusted HR= 0.65, 95%
CI= 0.49–0.87) (12). While the majority of patients included in
this study were isolated CABG, HRs were not provided by type of
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Table 1 | Patient characteristics.
Characteristic Black (n=970) White (n=3,460)
β-blocker n (%) No β-blocker n (%) β-blocker n (%) No β-blocker n (%)
Overall 853 (88) 117 (12) 3,038 (88) 422 (12)
Age (years)
Mean±SD, median (range) 61±10, 60 (33–86) 63±11, 63 (33–86)† 64±10, 64 (26–90) 67±10, 68 (28–89)††
Male 545 (64) 57 (49)
††
2,312 (76) 278 (66)
††
BMI (kg/m2)
Mean±SD, median (range) 31±6.3, 30 (17–55) 31±7.5, 30 (19–64) 30±5.5, 29 (13–54) 29±6.0, 29 (14–66)
Operative status (elective) 419 (49) 56 (48) 1,485 (49) 202 (48)
CAD severity
1 Vessel 60 (7) 4 (3) 211 (7) 24 (6)
2 Vessel 208 (24) 35 (30) 797 (26) 102 (24)
3 Vessel 585 (69) 78 (67) 2,030 (67) 296 (70)
Left main disease 240 (28) 24 (21) 782 (26) 128 (30)
Recent smoker 308 (36) 36 (31) 942 (31) 133 (32)
Hypertension 783 (92) 101 (86) 2,476 (82) 335 (79)
Diabetes 415 (49) 72 (62)
†
1,124 (37) 164 (39)
Heart failure 259 (30) 49 (42)
†
717 (24) 152 (36)
††
COPD 148 (17) 28 (24) 618 (20) 134 (32)
††
Peripheral arterial disease 144 (17) 21 (18) 464 (15) 89 (21)
††
Dialysis 57 (7) 14 (12) 24 (1) 7 (2)
Prior MI 441 (52) 68 (58) 1,435 (47) 237 (56)
††
Prior stroke 110 (13) 19 (16) 222 (7) 31 (7)
Prior PCI 216 (25) 30 (26) 728 (24) 111 (26)
† p<0.05.
† † p<0.01.
Statistical significance for categorical variables was tested using Fisher’s exact test and the Deuchler–Wilcoxon procedure for continuous variables.
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PCI, percutaneous coronary
intervention; SD, standard deviation.
Table 2 | Preoperative medications.
Medication Black (n=970) White (n=3,460)
β-blocker n (%) No β-blocker n (%) β-blocker n (%) No β-blocker n (%)
Preoperative β-blocker 691 (81) 81 (69)
††
2,358 (78) 276 (65)
††
Aspirin 665 (78) 83 (71) 2,472 (81) 318 (75)
††
Lipid-lowering agents 634 (74) 79 (68) 2,236 (74) 275 (65)
††
Anticoagulants 309 (36) 48 (41) 1,120 (37) 163 (39)
Antiplatelet agents 175 (21) 36 (31)
†
686 (23) 121 (29)
††
Calcium channel blockers 213 (25) 36 (31) 536 (18) 90 (21)
Diuretics 230 (27) 36 (31) 582 (19) 126 (30)
††
ACE inhibitors/ARBs 469 (55) 54 (46) 1,309 (43) 189 (45)
Digitalis 23 (3) 13 (11)
††
96 (3) 27 (6)
††
Nitrates 89 (10) 19 (16) 367 (12) 54 (13)
Inotropic agents 7 (1) 4 (3)
†
24 (1) 10 (2)
††
† p<0.05.
† † p<0.01.
Statistical significance for categorical variables was tested using Fisher’s exact test and the Deuchler–Wilcoxon procedure for continuous variables.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
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surgery. Additionally, racial differences were not examined in this
study, possibly due to the limited diversity of surgical populations
in western Canada.
β-Blockers were found to improve 1-year outcomes in patients
with chronic obstructive pulmonary disease (adjusted HR= 0.38,
p= 0.003) (13). In contrast with the current study, racial dif-
ferences were not reported and study populations were limited
to patients with chronic obstructive pulmonary disease. Addi-
tionally, patients undergoing CABG in the PREVENT IV trial
were surveyed for use of secondary prevention medications (e.g.,
antiplatelet agents, β-blockers, angiogtensin-converting enzyme
inhibitors or angiotensin receptor blockers, and lipid-lowering
agents) 1 year after hospital discharge and cardiac-related mor-
tality was assessed at 2 years (11). Although not statistically sig-
nificant, patients discharged with β-blockers observed a trend of
improved survival than those not receiving β-blockers (adjusted
HR= 0.53, 95% CI= 0.24–1.17). A survival advantage was not
Table 3 | Postoperative complications.
Complication Black (n=970) White (n=3,460)
β-blocker No β-blocker β-blocker No β-blocker
n (%) n (%) n (%) n (%)
MI 0 (0) 1 (1) 6 (<1) 3 (1)
Stroke 15 (2) 8 (7)
††
18 (1) 25 (6)
††
ARDS 4 (<1) 5 (4)
††
12 (<1) 31 (7)
††
Pneumonia 16 (2) 8 (7)
††
35 (1) 37 (9)
††
GI event* 40 (5) 11 (9)
†
58 (2) 40 (9)
††
Renal failure 18 (2) 10 (9)
††
38 (1) 39 (9)
††
† p<0.05.
† † p<0.01.
Statistical significance for categorical variables was tested using Fisher’s exact
test and the Deuchler–Wilcoxon procedure for continuous variables.
*Includes GI bleed, pancreatitis, cholecystitis, mesenteric ischemia, and other GI
events.
ARDS, acute respiratory distress syndrome; GI, gastrointestinal; MI, myocardial
infarction.
observed in post-CABG patients who were not ideal candidates
for β-blockers (adjusted HR= 1.19, 95% CI= 0.70–2.01).
Racial differences in the effectiveness of β-blockers in car-
diovascular patients have been reported in the literature. A
2-year follow-up study of heart failure patients receiving β-
blockers observed that white patients benefited more than black
patients (black: adjusted HR= 0.67, 95% CI= 0.48–0.94; white:
adjusted HR= 0.40, 95% CI= 0.27–0.60) (14). However, we
did not observe a statistically significant survival advantage for
white patients receiving β-blockers compared with blacks. Known
genetic polymorphisms in the β-adrenergic pathway possibly
explain reported inconsistencies in the literature (24, 25).
STRENGTHS AND LIMITATIONS
Our study is strengthened by its large racially dichotomous sam-
ple size and long-term follow-up. Furthermore, we were able to
accurately determine time of death using a combination of the
National Death Index and our comprehensive electronic medical
record.
Data regarding socioeconomic position, education, and income
were not collected and these factors potentially influenced survival
(26). Alcohol consumption also was not recorded in our dataset,
but this variable has not been associated with increased morbidity
and mortality after CABG (27). We did not have information on
long-term β-blocker use. Adherence to medication among study
participants may have changed. In general, β-blocker adherence
has been shown to be relatively stable after CABG and any non-
adherence to β-blockers after discharge likely would have biased
results toward the null, decreasing the probability of finding an
association of β-blocker use and long-term survival (28). How-
ever, a statistically significant result was observed in our study
despite potential non-adherence to β-blocker therapies.
Physicians may have prescribedβ-blockers to patients perceived
to have better prognoses, potentially introducing selection bias
into the analysis. However, the association of discharge β-blocker
use and lower mortality was preserved after excluding patients
who died within the first 30 days of surgery (black: adjusted
HR= 0.42, 95% CI= 0.28–0.61; white: adjusted HR= 0.71, 95%
CI= 0.56–0.90). Presumably, the accuracy of selecting patients
who will survive diminishes following the postoperative period.
FIGURE 1 | Unadjusted Kaplan–Meier survival among black patients by β-blocker discharge status.
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FIGURE 2 | Unadjusted Kaplan–Meier survival among white patients by β-blocker discharge status.
While β-blocker therapy is relatively contraindicated in patients
with chronic obstructive pulmonary disease and may have resulted
in selection bias, only a small number of these patients were not
discharged on β-blockers and this percentage was similar between
races. β-Blocker use also is relatively contraindicated in heart
failure patients with depressed ejection fraction (< 0.35). How-
ever, few patients with depressed ejection fraction who did not
receive β-blockers were in our dataset (black, 2.5%; white, 2.2%).
Excluding these patients did not substantively alter our findings
(black, adjusted HR= 0.29, 95% CI= 0.20–0.43; white, adjusted
HR= 0.48, 95% CI= 0.38–0.60).
Patients in this study were recruited over a relatively long
period (~10 years), during which practice methods and clinical
care may have changed. However, adjusting for study period had
little impact on our findings. Similarly, the status of several vari-
ables in our analysis may have changed over time (e.g., medications
and postoperative complications). We did not adjust for these vari-
ables in a time-dependent manner due to their potential to be in
the causal pathway. Cause of death is not recorded in the National
Death Index and β-blocker use may have been unrelated to their
mortality. Although we adjusted for known clinically relevant vari-
ables, we acknowledge that other unmeasured factors may have
resulted in residual confounding. Additionally, the data reported
are from a single center and may reflect a chance finding specific
to our institution and region.
Multivariable Cox regression models were used to adjust for
confounding because of potential “non-collapsibility bias” inher-
ent to propensity scores based on log-linear models and the
possible decrease in power due to incomplete matching (29).
Additionally, a random forest algorithm (e.g., machine learning)
was not used for matching. This algorithm potentially introduces
misspecification bias into the propensity score model due to the
“black box” nature of the algorithm that obscures the etiologic
relationship between predictors and outcome (30, 31).
In conclusion, β-blocker use at discharge was associated with
a survival advantage among black patients after CABG and the
magnitude of the effect was similar to that observed among white
patients. In contrast with prior studies that have reported β-
blocker use is less effective in black patients, we did not observe a
similar association at our institution among black CABG patients
discharged on β-blockers. Additional studies are needed to bet-
ter understand the underlying mechanisms of our results and
to appropriately target future treatment strategies among CABG
patients.
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